# US 2025/0228907 A1 · Compositions and methods for treating metachromatic leukodystrophy disease and related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0228907 A1
- Document ID: US20250228907A1
- Status: Published application
- Kind: A1
- Application number: 18/700,122
- Filed: 2022-11-03
- Published: 2025-07-17
- Earliest claimed: 2021-11-04
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Stefano Rivella; Lucas Tricoli
- Web page: https://patentgrep.com/patent/US20250228907A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 9/00: Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
- C12N 9/0051: {acting on a sulfur group of donors (1.8)}
- C12N 9/0089: {acting on superoxide as acceptor (1.15)}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/86: Viral vectors
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/446: {Superoxide dismutase (1.15)}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2830/40: being an insulator
- C12Y 108/99: with other acceptors (1.8.99)
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- C12Y 301/06001: Arylsulfatase (3.1.6.1)
- C12Y 302/01046: Galactosylceramidase (3.2.1.46)
- C12Y 310/01001: N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention provides compositions and methods for the treatment of lysosomal storage diseases such as metachromatic leukodystrophy and related disorders. A significant unmet clinical need still exists with the current clinical lentiviral vectors due to the high integration requirement and currently insufficient levels of ARSA expression to correct onset of early symptomatic disease. Methods and compositions for producing a protein such as sulfatase and for treating a disease or disorder such as metachromatic leukodystrophy and related disorders are disclosed.

## Claims

### Claim at position 1

1: A lentiviral vector comprising a nucleic acid molecule comprising:
i) a 5′ long terminal repeat (LTR) and a 3′ LTR, wherein at least one of said LTR is self-inactivating;
ii) an Elongation Factor 1 alpha (EF1-alpha) promoter or CD68 promoter;
iii) an insulator element;
iv) a nucleic acid sequence encoding a therapeutic protein;
v) a Woodchuck Post-Regulatory Element (WPRE); and
vi) a polyadenylation signal.

### Claim at position 2 (depends on 1)

2: The lentiviral vector of claim 1, wherein said therapeutic protein is sulfatase and/or formylglycine-generating enzyme (FGE).

### Claim at position 3 (depends on 2)

3: The lentiviral vector of claim 2, wherein said sulfatase is arylsulfatase A (ARSA).

### Claim at position 4 (depends on 1)

4: The lentiviral vector of claim 1, wherein said insulator element is an ankyrin insulator element (Ank) or a foamy virus insulator element.

### Claim at position 5 (depends on 1)

5: The lentiviral vector of claim 1, wherein said insulator element is within the 3′ LTR.

### Claim at position 6 (depends on 1)

6: The lentiviral vector of claim 1, wherein said insulator element is between said 5′ LTR and said promoter.

### Claim at position 7 (depends on 1)

7: The lentiviral vector of claim 1 comprising a nucleic acid sequence encoding a sulfatase and a nucleic acid sequence encoding formylglycine-generating enzyme (FGE).

### Claim at position 8 (depends on 1)

8: The lentiviral vector of claim 1, wherein said therapeutic protein is selected from the group consisting of ATP binding cassette subfamily D member 1 (ABCD1), N-sulfoglucosamine sulfohydrolase (SGSH), galactocerebrosidase (GALC), and superoxide dismutase 1 gene (SOD1).

### Claim at position 9 (depends on 1)

9: A cell comprising the lentiviral vector of claim 1.

### Claim at position 10 (depends on 9)

10: The cell of claim 9, wherein the cell has been isolated from bone marrow.

### Claim at position 11 (depends on 1)

11: A composition comprising the lentiviral vector of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 12 (depends on 1)

12: A composition comprising viral particles, wherein the viral particles comprise the lentiviral vector of claim 1.

### Claim at position 13 (depends on 1)

13: A method of inhibiting, treating, and/or preventing multiple sulfatase deficiency (MSD), metachromatic leukodystrophy (MLD) and/or a sulfatase deficiency in a subject, said method comprising administering the lentiviral vector of claim 1 to the subject.

### Claim at position 14 (depends on 13)

14: The method of claim 13, wherein said cells are selected from the group consisting of hematopoietic stem cells, bone marrow cells, microglia, and fibroblasts.

### Claim at position 15 (depends on 13)

15: The method of claim 13, wherein the cells are isolated from the subject to be treated.

### Claim at position 16 (depends on 1)

16: A method of inhibiting, treating, and/or preventing a disease or disorder in a subject, said method comprising administering the lentiviral vector of claim 1 to the subject.

### Claim at position 17 (depends on 16)

17: The method of claim 16, wherein said disease or disorder is adrenoleukodystrophy (ALD) and the therapeutic protein is ATP binding cassette subfamily D member 1 (ABCD1).

### Claim at position 18 (depends on 1)

18: A method of inhibiting, treating, and/or preventing multiple sulfatase deficiency (MSD), metachromatic leukodystrophy (MLD) and/or a sulfatase deficiency in a subject, said method comprising introducing the lentiviral vector of claim 1 into cells and delivering the cells to the subject.

### Claim at position 19 (depends on 1)

19: A method of inhibiting, treating, and/or preventing a disease or disorder in a subject, said method comprising introducing the lentiviral vector of claim 1 into cells and delivering the cells to the subject.
